Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Autor: Zingone A; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wang W; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Corrigan-Cummins M; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Wu SP; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Plyler R; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Korde N; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kwok M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Manasanch EE; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Tageja N; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bhutani M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mulquin M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zuchlinski D; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yancey MA; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Roschewski M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zhang Y; Dana-Faber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA., Roccaro AM; Dana-Faber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA., Ghobrial IM; Dana-Faber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA., Calvo KR; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Landgren O; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: landgrec@mskcc.org.

Publikováno v: Cytokine [Cytokine] 2014 Oct; Vol. 69 (2), pp. 294-7. Date of Electronic Publication: 2014 Jul 17.

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Autor: Rajan A; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA., Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Apr 15; Vol. 18 (8), pp. 2344-51. Date of Electronic Publication: 2012 Feb 27.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Autor: Kummar S; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. kummars@mail.nih.gov, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2010 Jan; Vol. 46 (2), pp. 340-7. Date of Electronic Publication: 2009 Nov 27.